Thermo Fisher Scientific to Acquire Phadia, a Global Leader in Allergy and Autoimmunity Diagnostics

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to acquire Phadia, a global leader in allergy and autoimmunity diagnostics, from European private equity firm Cinven, for €2.47 billion (or approximately $3.5 billion) in cash.

Click this link to read the Thermo Fisher Scientific Press Release



As in all diagnostic testing, the diagnosis is made by the physican based on both test results and the patient history.